Free Silicone-Induced Granulomatosis and Hypercalcemia in a Transgender Female.

Introduction: Vitamin D derangements are a rare but important cause of hypercalcemia. Granulomatous disease is a primary cause of vitamin D derangements and is frequently associated with sarcoidosis, tuberculosis, and in the present case, foreign body granulomatosis. Liquid or injectable silicone is used as a filler for cosmetic body contouring. Transgender patients may seek silicone injections as part of gender affirmation surgeries. Granuloma formation is a rare but well-described complication of injectable silicone. Case Description: A 40-year-old, assigned male at birth (AMAB) transgender female patient, with a history of HIV and chronic kidney disease (CKD) stage 3b, was admitted to the emergency department for evaluation of hypercalcemia. One year prior, the hypercalcemia was attributed to CKD secondary to HIV or HIV medications. The patient presented after two weeks of polyuria and polydipsia. Her vital signs were stable, and the physical exam, EKG, and chest x-ray were unremarkable. Labs were notable for calcium (14.1 mg/dL, assay normal range 8.5-10.5 mg/dL) and acute-on-chronic kidney disease. Follow-up labs were consistent with a vitamin D aberration causing hypercalcemia, raising suspicion for granulomatous disease. CT chest/abdomen/pelvis without contrast demonstrated diffuse skin thickening of the bilateral breasts and buttocks with associated ill-defined soft tissue density and scattered punctate calcifications. No hilar adenopathy or lung abnormalities were observed, decreasing the suspicion of sarcoidosis or an infectious etiology. The patient disclosed having received free silicone injections to which the hypercalcemia was attributed. After single doses of calcitonin (100U SC/IM) and zoledronic acid (4 mg IV), her hypercalcemia resolved. Kidney function gradually returned to baseline with IV fluids. Conclusion: This case illustrates the importance of readily recognizing the imaging characteristics of free silicone granulomatosis, which showed subcutaneous fat infiltrated with soft tissue nodules and calcifications. The distribution of findings in the bilateral breast and buttocks and history of free silicone injections were most useful in arriving at a diagnosis and treatment plan.

Validity of Current Stereotactic Body Radiation Therapy Dose Constraints for Aorta and Major Vessels.

Understanding dose constraints for critical structures in stereotactic body radiation therapy (SBRT) is essential to generate a plan for optimal efficacy and safety. Published dose constraints are derived by a variety of methods, including crude statistics, actuarial analysis, modeling, and simple biologically effective dose (BED) conversion. Many dose constraints reported in the literature are not consistent with each other, secondary to differences in clinical and dosimetric parameters. Application of a dose constraint without discriminating the variation of all the factors involved may result in suboptimal treatment. This issue of Seminars in Radiation Oncology validates dose tolerance limits for 10 critical anatomic structures based on dose response modeling of clinical outcomes data to include detailed dose-volume metrics. This article presents a logistic dose-response model for aorta and major vessels based on 238 cases from the literature in addition to 387 cases from MD Anderson Cancer Center at Cooper University Hospital, for a total of 625 cases. The Radiation Therapy Oncology Group (RTOG) 0813 dose-tolerance limit of Dmax = 52.5Gy in 5 fractions was found to have a 1.2% risk of grade 3-5 toxicity, and the Timmerman 2008 limit of Dmax = 45Gy in 3 fractions had 2.3% risk. From the model, the 1% and 2% risk levels for D4cc, D1cc, and D0.5cc are also provided in 1-5 fractions, in the form of a dose-volume histogram (DVH) Risk Map.

Occult pelvic lymph node involvement in bladder cancer: implications for definitive radiation.

PURPOSE: To inform radiation treatment planning for clinically staged, node-negative bladder cancer patients by identifying clinical factors associated with the presence and location of occult pathologic pelvic lymph nodes. METHODS AND MATERIALS: The records of patients with clinically staged T1-T4N0 urothelial carcinoma of the bladder undergoing radical cystectomy and pelvic lymphadenectomy at a single institution were reviewed. Logistic regression was used to evaluate associations between preoperative clinical variables and occult pathologic pelvic or common iliac lymph nodes. Percentages of patient with involved lymph node regions entirely encompassed within whole bladder (perivesicular nodal region), small pelvic (perivesicular, obturator, internal iliac, and external iliac nodal regions), and extended pelvic clinical target volume (CTV) (small pelvic CTV plus common iliac regions) were calculated. RESULTS: Among 315 eligible patients, 81 (26%) were found to have involved pelvic lymph nodes at the time of surgery, with 38 (12%) having involved common iliac lymph nodes. Risk of occult pathologically involved lymph nodes did not vary with clinical T stage. On multivariate analysis, the presence of lymphovascular invasion (LVI) on preoperative biopsy was significantly associated with occult pelvic nodal involvement (odds ratio 3.740, 95% confidence interval 1.865-7.499, P<.001) and marginally associated with occult common iliac nodal involvement (odds ratio 2.307, 95% confidence interval 0.978-5.441, P=.056). The percentages of patients with involved lymph node regions entirely encompassed by whole bladder, small pelvic, and extended pelvic CTVs varied with clinical risk factors, ranging from 85.4%, 95.1%, and 100% in non-muscle-invasive patients to 44.7%, 71.1%, and 94.8% in patients with muscle-invasive disease and biopsy LVI. CONCLUSIONS: Occult pelvic lymph node rates are substantial for all clinical subgroups, especially patients with LVI on biopsy. Extended coverage of pelvic lymph nodes up to the level of the common iliac nodes may be warranted in subsets of patients.

Discordance between preoperative and postoperative bladder cancer location: implications for partial-bladder radiation.

PURPOSE: There is strong interest in partial-bladder radiation whether as a boost or definitive therapy to limit long-term toxicity. It is unclear that a standard preoperative examination can accurately identify all sites of disease within the bladder. The purpose of this study was to determine the correlation between preoperative localization of bladder tumors with postoperative findings to facilitate partial-bladder radiation techniques when appropriate. METHODS AND MATERIALS: We examined patients with clinically staged T1-T4 invasive transitional cell carcinoma (TCC) or TCC with variant histology with no history of radiation or partial cystectomy undergoing radical cystectomy. Patients were scored as "under-detected" if a bladder site was involved with invasive disease (≥T1) at the time of cystectomy, but not identified preoperatively. Patients were additionally scored as "widely under-detected" if they had postoperative lesions that were not identified preoperatively in a given site, nor in any adjacent site. Rates of under-detected and widely under-detected lesions, as well as univariate and multivariate association between clinical variables and under-detection, were evaluated using logistic regression. RESULTS: Among 222 patients, 96% (213/222) had at least 1 area of discordance. Fifty-eight percent of patients were under-detected in at least 1 location, whereas 12% were widely under-detected. Among 24 patients with a single site of disease on preoperative evaluation, 21/24 (88%) had at least 1 under-detected lesion and 14/24 (58%) were widely under-detected. On multivariate analysis, only solitary site of preoperative disease was associated with increased levels of under-detection of invasive disease (OR = 4.161, 95% CI, 1.368-12.657). CONCLUSION: Our study shows a stark discordance between preoperative and postoperative localization of bladder tumors. From a clinical perspective, incomplete localization of all sites of disease within the bladder may lead to marginal misses when a partial-bladder technique is used.

Radiotherapy Planning Complexity and Survival after Treatment of Advanced Stage Lung Cancer in the Elderly.

PURPOSE: Complex radiotherapy (RT) planning is increasingly common in the treatment of lung cancer though it remains unclear if these treatments are associated with better outcomes. We evaluated the association between the complexity of RT planning simulation with survival among elderly Stage IIIB non-small cell lung cancer (NSCLC) patients. METHODS: We included all patients aged >65 years with histologically confirmed Stage IIIB NSCLC diagnosed between 1992 and 2002 receiving chemotherapy and RT from the Surveillance, Epidemiology, and End Results registry linked to Medicare claims. Patients were divided into simple, intermediate, and complex RT planning groups using Medicare physician codes. Kaplan-Meier curves and Cox regression were used to compare overall and lung cancer-specific survival rates across groups. RESULTS: We identified 1,733 patients: 148 (8%), 1,138 (66%), and 447 (26%) were classified as having received simple, intermediate and complex RT planning, respectively. Baseline characteristics were similar across groups. Increasing complexity of RT planning was significantly associated with better overall survival (p=0.0002). Multivariate analyses showed that intermediate (HR: 0.75, 95% CI: 0.62 to 0.91) and complex planning (HR: 0.69, 95% CI: 0.55 to 0.86) were associated with better overall survival compared to simple RT planning. Similar results were observed for lung cancer-specific survival analyses. Toxicities were comparable across groups. CONCLUSIONS: The use of more complex RT planning and simulation methods is associated with better survival in elderly patients with Stage IIIB NSCLC. Although these results should be further validated in prospective clinical trials, this data suggests that complex planning may improve the outcomes of these patients.

Variability in access to hospital palliative care in the United States.

BACKGROUND: Hospital palliative care programs provide high-quality, comprehensive care for seriously ill patients and their families. OBJECTIVE: To examine geographic variation in patient and medical trainee access to hospital palliative care and to examine predictors of these programs. METHODS: Primary and secondary analyses of national survey and census data. Hospital data including hospital palliative care programs were obtained from the American Hospital Association (AHA) Annual Survey Databasetrade mark for fiscal year 2006 supplemented by mailed surveys. Medical school-affiliated hospitals were obtained from the American Association of Medical Colleges, Web-site review, and telephone survey. Health care utilization data were obtained from the Dartmouth Atlas of Health Care 2008. Multivariate logistic regression was used to identify characteristics significantly associated with the presence of hospital palliative care. RESULTS: A total of 52.8% of hospitals with 50 or more total facility beds reported hospital palliative care with considerable variation by state; 40.9% (144/352) of public hospitals, 20.3% (84/413) of for-profit hospitals, and 28.8% (160/554) of Medicare sole community providers reported hospital palliative care. A total of 84.5% of medical schools were associated with at least one hospital palliative care program. Factors significantly associated (p < 0.05) with hospital palliative care included geographic location, owning a hospice program, having an American College of Surgery approved cancer program, percent of persons in the county with a university education, and medical school affiliation. For-profit and public hospitals were significantly less likely to have hospital palliative care when compared with nonprofit institutions. States with higher hospital palliative care penetration rates were observed to have fewer Medicare hospital deaths, fewer intensive care unit/cardiac care unit (ICU/CCU) days and admissions during the last 6 months of life, fewer ICU/CCU admission during terminal hospitalizations, and lower overall Medicare spending/enrollee. DISCUSSION: This study represents the most recent estimate to date of the prevalence of hospital palliative care in the United States. There is wide geographic variation in access to palliative care services although factors predicting hospital palliative care have not changed since 2005. Overall, medical students have high rates of access to hospital palliative care although complete penetration into academic settings has not occurred. The association between hospital palliative care penetration and lower Medicare costs is intriguing and deserving of further study.